# Treatment methods for epidermolysis bullosa
Treatment of epidermolysis bullosa focuses mainly on wound care, infection prevention, and symptom management. Because the underlying genetic cause cannot be corrected, treatments usually aim at relieving complaints and preventing complications. The approach varies depending on the type and severity of the disease.
Wound care and local measures
**Wound cleansing and dressing changes**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular cleansing of open wounds and blister sites forms the cornerstone of daily care. This is usually done with mild soap and clean water or sterile saline solution. After cleansing, wounds are often covered with special dressing material that provides moisture regulation and protection. The goal is to prevent infections, limit pain, and promote healing. The choice of dressing material depends on wound type and location; many patients use silicone, foam, or hydrocolloid dressings. Possible side effects are minimal, but dressing changes can cause pain, especially in severe forms of the disease.
**Topical antibacterial agents**
ProveniIncluded in official guidelines, or approved by EMA or FDA
In case of bacterial infection or for its prevention, topical antibacterial substances are applied, including silver-containing dressings and in some cases gentamicin. Recent studies examine the use of gentamicin in topical form for wound healing; this is not yet standard practice and is mainly investigated in specialized centers. Side effects of topical agents are usually limited to local irritation or allergy to certain substances.
**Bandaging and compression therapy**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Adapted bandaging techniques and targeted compression clothing help limit blister formation and prevent skin contractures (shortening). This also includes specialized braces and orthoses, for example for hands and feet. A recent study described the benefit of adapted soft braces after surgical intervention for hand contractures. These measures contribute to mobility and prevent severe deformities, although they require regular adjustment.
Surgical Interventions
**Release of scars and contractures**
ProveniIncluded in official guidelines, or approved by EMA or FDA
In case of severe scarring or movement restriction, surgical interventions may be considered to release skin and restore more freedom of movement. This applies especially to hands and fingers. A long-term follow-up study showed that repeated surgical interventions in patients with recessive dystrophic EB can maintain foot function over years. Risks include blister formation after the procedure and recurrence of scars.
**Skin transplantation**
ProveniIncluded in official guidelines, or approved by EMA or FDA
In case of large-scale wound loss, surgical skin transplantation may be considered. This can consist of autologous skin (skin from the patient's own body) or biological replacement materials. In certain severe forms of EB, however, success is limited because the underlying genetic disorder remains present.
Systemic medications
**Pain management**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Because wound treatment and blister formation can cause significant pain, analgesics (painkillers) are used at various levels. This can range from mild to strong agents, depending on the degree of pain and the situation. Side effects depend on the specific agent and may include constipation and drowsiness.
**Ivermectin (experimental use)**
ResearchediPositive results in clinical studies, not yet standard treatment
A recent study described the use of ivermectin in junctional EB, with indications for improved wound healing and reduced itching. This is not standard treatment and is being investigated in specific research settings. Side effects may include headache, dizziness, and abdominal complaints.
**Laxatives**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many patients with EB, especially children, are prescribed laxatives (bowel-enhancing agents) because the disease and certain medications can cause constipation. This is supportive care aimed at comfort and prevention of complications.
**Antibiotic treatment of infections**
ProveniIncluded in official guidelines, or approved by EMA or FDA
When wounds become bacterially contaminated, systemic antibiotics are prescribed. The choice depends on the type of bacteria. Side effects may include allergy, gastrointestinal disorders and (with long-term use) resistance development.
Nutrition and oral health care
**Oral care and dental management**
ProveniIncluded in official guidelines, or approved by EMA or FDA
In certain EB forms (especially junctional and mutilans types), blisters in and around the mouth can be severe, making eating, drinking and tooth brushing difficult. Special oral hygiene measures and regular dental check-ups are important. Recent guidelines describe specialized oral care for inherited bullous disorders.
**Nutritional support**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many patients have difficulty eating due to blisters in the mouth and oesophagus. Nutritional counselling and sometimes supplementary nutritional drinks help prevent malnutrition. In very severe forms, tube feeding may be necessary.
Medicines under investigation and innovative therapies
**Gene therapy**
ExperimentaliOngoing in study setting, outcome still unknown
Gene therapy for dystrophic EB is in the experimental phase. The principle is to repair the defective gene in which type VII collagen (skin anchor protein) is coded. Various studies are ongoing; some show promising results in stimulating wound healing. This is currently not available outside clinical trial schemes.
**Stem cell therapy and gene modification**
ExperimentaliOngoing in study setting, outcome still unknown
Treatments targeting skin stem cells and gene modification techniques (including CRISPR) are being investigated. Research focuses on the potential of modified hair cells or skin cells with normally functioning genes that are replanted. This is not yet standard.
**Growth and healing factors**
ResearchediPositive results in clinical studies, not yet standard treatment
Various studies focus on factors that can stimulate wound healing, including in combination with photodynamic therapy. This approach is in early research stages.
**Medications targeting fibrosis and scarring**
ResearchediPositive results in clinical studies, not yet standard treatment
Some studies focus on inhibiting excessive scar formation and fibrosis (connective tissue hardening) by blocking certain pathways. This is not yet in wide clinical use.
Supportive care
**Psychological support**
ProveniIncluded in official guidelines, or approved by EMA or FDA
EB is accompanied by significant psychological burden: pain, visible scars, movement restrictions and regular hospital visits. Psychological support, with or without psychopharmaceuticals (such as antidepressants), is part of integrated care. Recent studies emphasize the impact on quality of life for children and adults.
**Physiotherapy and occupational therapy**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Exercise therapy and ergonomic adjustments help maintain mobility and prevent contractures. This is particularly relevant for severity grade III conditions with extensive scarring.
**Infection prevention and hygiene**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Good hygiene and caution around wounds are essential. Screening for certain bacterial species may be necessary, especially in hospital settings.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._